April 7, 2014
/PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax
anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which PharmAthene will evaluate its options with respect to its SparVax
PharmAthene has been developing SparVax
to address a requirement for a modern anthrax vaccine based on state-of-the-art vaccine technology. The decision follows an In Process Review (IPR) meeting where, despite the Food and Drug Administration (FDA) placing SparVax
on clinical hold, PharmAthene reported progress on the SparVax
program. Since the previous IPR meeting in 2011, PharmAthene has demonstrated the following achievements:
- Development of a high yield GMP manufacturing process with the capability to deliver >150 million doses annually to the Strategic National Stockpile
- Equivalent survival to BioThrax ® in a New Zealand White rabbit anthrax aerosol spore challenge model
- Minimum two year stability and potency of SparVax ®
- Development of novel analytical assays; a new immunopotency assay has been accepted by the FDA to measure anthrax vaccine stability
- Economic advantage over the currently licensed vaccine offering potential savings of up to $750 million to taxpayers
- Establishment of surge capacity for manufacturing
Phase 1 and Phase 2 clinical trials involving 770 healthy subjects have demonstrated that SparVax
appears to be well tolerated and capable of producing an immune response in humans.
These studies suggest that three doses of SparVax
should be sufficient to induce protective immunity. Non-clinical animal studies of SparVax
have demonstrated the capability to protect rabbits and non-human primates against lethal anthrax aerosol spore challenge.
Eric I. Richman
, President and Chief Executive Officer, stated, "We believe that SparVax
is the most advanced next generation anthrax vaccine currently in development and we intend to explore all of our options, including seeking partnering or financing opportunities to continue our development efforts. We await more information from BARDA."
PharmAthene's rPA anthrax vaccine program has been supported by funding from the National Institute of Allergy and Infectious Disease, National Institutes of Health, and the Biomedical Advanced Research and Development Authority.